Open AccessPredictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials
Author(s) -
Florence Lerebours,
Marina Pulido,
Emmanuelle Fourme,
Marc Debled,
Véronique Becette,
Hervé Bonnefoi,
Sofía Rivera,
Gaëtan MacGrogan,
Marie-Ange Mouret-Reynier,
C. Tu de Lara,
JeanYves Pierga,
C. Breton-Callu,
Laurence Vénat-Bouvet,
Simone MathoulinPélissier,
Thibault De La Motte Rouge,
Florence Dalenc,
Brigitte Sigal,
Thomas Bachelot,
Jérôme Lemonnier,
Nathalie Quénel-Tueux
Publication year - 2020
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/s41416-020-0733-x
Subject(s) - medicine , breast cancer , hazard ratio , oncology , anastrozole , neoadjuvant therapy , tamoxifen , univariate analysis , multivariate analysis , chemotherapy , cancer , fulvestrant , surgery , confidence interval
Few data are available on survival and predictive factors in early breast cancer (BC) patients treated with neoadjuvant endocrine therapy (NET).